<DOC>
	<DOCNO>NCT00817778</DOCNO>
	<brief_summary>The purpose study assess 1 month safety tolerability multiple oral dos AZD1656 patient Type 2 Diabetes Mellitus Treated Metformin</brief_summary>
	<brief_title>Study Assess Safety Tolerability After Multiple Oral Doses AZD1656 Patients With Type 2 Diabetes Mellitus Treated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male woman nonchildbearing potential ( postmenopausal , and/or undergone hysterectomy and/or bilateral oophorectomy salpingectomy/ tubal ligation ) Ongoing treatment metformin stable dose ≥ 1500 mg/day least 8 week prior randomisation HbA1c ≤ 10 % enrolment ( HbA1c value accord international Diabetes Control Complications Trial [ DCCT ] standard ) History ischemic heart disease , symptomatic heart failure , stroke , transitory ischemic attack symptomatic peripheral vascular disease Clinically significant abnormality ECG , clinical chemistry , haematology , urine analysis result . Positive test Hepatitis B surface antigen antibody human immunodeficiency virus ( HIV ) antibodies Hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Type II Diabetes</keyword>
</DOC>